493 related articles for article (PubMed ID: 32247816)
1. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
[TBL] [Abstract][Full Text] [Related]
3. Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.
Finlay DB; Nguyen T; Gamage TF; Chen S; Barrus DG; Patel PR; Thomas BF; Wiley JL; Zhang Y; Glass M
Pharmacol Res Perspect; 2022 Feb; 10(1):e00901. PubMed ID: 35041297
[TBL] [Abstract][Full Text] [Related]
4. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
[TBL] [Abstract][Full Text] [Related]
5. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
6. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
7. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
Canazza I; Ossato A; Trapella C; Fantinati A; De Luca MA; Margiani G; Vincenzi F; Rimondo C; Di Rosa F; Gregori A; Varani K; Borea PA; Serpelloni G; Marti M
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3685-3709. PubMed ID: 27527584
[TBL] [Abstract][Full Text] [Related]
8. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
9. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
10. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
11. Sex, species and age: Effects of rodent demographics on the pharmacology of ∆
Wiley JL; Barrus DG; Farquhar CE; Lefever TW; Gamage TF
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110064. PubMed ID: 32810571
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
13. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
15. The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB
Gamage TF; Farquhar CE; Lefever TW; Thomas BF; Nguyen T; Zhang Y; Wiley JL
Neuropharmacology; 2017 Oct; 125():365-375. PubMed ID: 28803965
[TBL] [Abstract][Full Text] [Related]
16. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
[TBL] [Abstract][Full Text] [Related]
17. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
[TBL] [Abstract][Full Text] [Related]
19. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
[TBL] [Abstract][Full Text] [Related]
20. Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.
Thomas BF; Lefever TW; Cortes RA; Grabenauer M; Kovach AL; Cox AO; Patel PR; Pollard GT; Marusich JA; Kevin RC; Gamage TF; Wiley JL
J Pharmacol Exp Ther; 2017 Apr; 361(1):162-171. PubMed ID: 28087785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
